We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Robert Half (RHI) This Earnings Season?
Read MoreHide Full Article
Robert Half International Inc.’s (RHI - Free Report) shares have depreciated 31.5% year to date compared with the 36.2% decline of the industry it belongs to. The company is scheduled to report first-quarter 2020 results on Apr 23, after the bell.
Here’re the Expectations
The Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $1.5 billion, indicating growth of 2.3% year over year. The company has been witnessing momentum in its U.S. staffing and Protiviti operations, a trend that is most likely to have continued in the first quarter as well. Tight labor markets across the globe are expected to have kept demand for Robert Half’s professional staffing services in good shape during the quarter.
In fourth-quarter 2019, total revenues of $1.54 billion increased 3.8% year over year.
The consensus estimate for earnings stands at 81 cents, indicating a year-over-year decline of 12.9%. Rise in selling, general and administrative expenses due to negative leverage from the company’s non-U.S. staffing operations is expected to have strained the bottom line.
In fourth-quarter 2019, earnings of 98 cents per share increased 3.2% year over year.
What Our Model Says
Our proven Zacks model does not conclusively predict an earnings beat for Robert Half this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Robert Half has an Earnings ESP of -8.95% and currently carries a Zacks Rank #5.
Stocks to Consider
Here are a few stocks from the broader Zacks Business Services sector that investors may consider as our model shows that these have the right combination of elements to beat on first-quarter 2020 earnings:
Spotify (SPOT - Free Report) has an Earnings ESP of +26.78% and currently holds a Zacks Rank of 3.
Advanced Disposal has an Earnings ESP of +16.67% and currently carries a Zacks Rank of 3.
Verisk Analytics (VRSK - Free Report) has an Earnings ESP of +2.43% and is a Zacks #3 Ranked stock.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
What's in Store for Robert Half (RHI) This Earnings Season?
Robert Half International Inc.’s (RHI - Free Report) shares have depreciated 31.5% year to date compared with the 36.2% decline of the industry it belongs to. The company is scheduled to report first-quarter 2020 results on Apr 23, after the bell.
Here’re the Expectations
The Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $1.5 billion, indicating growth of 2.3% year over year. The company has been witnessing momentum in its U.S. staffing and Protiviti operations, a trend that is most likely to have continued in the first quarter as well. Tight labor markets across the globe are expected to have kept demand for Robert Half’s professional staffing services in good shape during the quarter.
In fourth-quarter 2019, total revenues of $1.54 billion increased 3.8% year over year.
Robert Half International Inc. Revenue (TTM)
Robert Half International Inc. revenue-ttm | Robert Half International Inc. Quote
The consensus estimate for earnings stands at 81 cents, indicating a year-over-year decline of 12.9%. Rise in selling, general and administrative expenses due to negative leverage from the company’s non-U.S. staffing operations is expected to have strained the bottom line.
In fourth-quarter 2019, earnings of 98 cents per share increased 3.2% year over year.
What Our Model Says
Our proven Zacks model does not conclusively predict an earnings beat for Robert Half this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Robert Half has an Earnings ESP of -8.95% and currently carries a Zacks Rank #5.
Stocks to Consider
Here are a few stocks from the broader Zacks Business Services sector that investors may consider as our model shows that these have the right combination of elements to beat on first-quarter 2020 earnings:
Spotify (SPOT - Free Report) has an Earnings ESP of +26.78% and currently holds a Zacks Rank of 3.
Advanced Disposal has an Earnings ESP of +16.67% and currently carries a Zacks Rank of 3.
Verisk Analytics (VRSK - Free Report) has an Earnings ESP of +2.43% and is a Zacks #3 Ranked stock.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>